Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Burkitt Lymphoma 3Leukemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Cyclophosphamide 8Mycophenolic Acid 6Whole-Body Irradiation 5Busulfan 5fludarabine phosphate 4fludarabine 4Tacrolimus 4Cyclosporine 4Rituximab 3Etoposide 3Cytarabine 3venetoclax 2ruxolitinib 2pegfilgrastim 2blinatumomab 2asciminib 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Methotrexate 2Inotuzumab Ozogamicin 2Filgrastim 2tocilizumab 1ricolinostat 1rasburicase 1pembrolizumab 1pegylated granulocyte colony-stimulating factor, human 1nilotinib 1idelalisib 1ibrutinib 1ceralasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia × Inotuzumab Ozogamicin × 30 days × Clear all
NCT05645718 2026-05-19

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
27 enrolled
Other hematologic neoplasm

Leukemia

NCT05748171 2026-05-14

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

Pfizer

Phase 2 Recruiting
100 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡